SCHEMBL6711629

SCHEMBL6711629

Cc1sc2ncnc(NN)c2c1C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.62
MEN1 O00255 4/20 0.62
KMT2A Q03164 4/20 0.62
RAF1 P04049 3/20 0.62
LMNA P02545 3/20 0.62
LIMK1 P53667 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
MAPT P10636 6/20 0.60
MAPK1 P28482 5/20 0.60
HTT P42858 2/20 0.60
HPGD P15428 1/20 0.60
GAA P10253 3/20 0.57
ALDH1A1 P00352 5/20 0.56
NPSR1 Q6W5P4 1/20 0.56
IRAK4 Q9NWZ3 1/20 0.52
RAB9A P51151 1/20 0.52
PIP4K2C Q8TBX8 1/20 0.52
ESR1 P03372 1/20 0.51
POLB P06746 1/20 0.51
ALOX15 P16050 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13165061 0.84 SMN1; SMN2 (0.64) SMN1; SMN2MEN1KMT2ARAF1LMNA
SCHEMBL1622168 0.76 LIMK1 (1.00) SMN1; SMN2MEN1KMT2ARAF1LMNA
SCHEMBL6911943 0.75 LIMK1 (0.66) SMN1; SMN2MEN1KMT2ARAF1LMNA
SCHEMBL13165134 0.73 SMN1; SMN2 (0.65) SMN1; SMN2MEN1KMT2ARAF1LMNA
SCHEMBL13164961 0.73 IRAK4 (0.72) SMN1; SMN2MEN1KMT2ARAF1LMNA
SCHEMBL10325795 0.72 IRAK4 (0.74) SMN1; SMN2MEN1KMT2ARAF1LMNA
SCHEMBL19523694 0.72 IRAK4 (0.74) SMN1; SMN2MEN1KMT2ARAF1LMNA
SCHEMBL1604779 0.72 LIMK1 (0.61) SMN1; SMN2MEN1KMT2ARAF1LMNA
SCHEMBL13644138 0.72 LIMK1 (0.61) SMN1; SMN2MEN1KMT2ARAF1LMNA
SCHEMBL6642198 0.72 LIMK1 (0.61) SMN1; SMN2MEN1KMT2ARAF1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040053977-A1 Medicinal uses of hydrazones ALMSTEAD JI-IN KIM (US) 2004-03-18 US disclosed
US-6660737-B2 Antihypoxic agents THE PROCTER & GAMBLE COMPANY 2003-12-09 US disclosed
US-20030092716-A1 Medicinal uses of hydrazones THE PROCTER & GAMBLE COMPANY 2003-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053977-A1 Medicinal uses of hydrazones PGF, VEGFA, TEK SMN1; SMN2 2892/4885MEN1 1753/4885KMT2A 3683/4885
US-20030092716-A1 Medicinal uses of hydrazones EPOR, VEGFA, HIF1A SMN1; SMN2 2163/4885MEN1 1904/4885KMT2A 4156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.